XHKG
0286
Market cap29mUSD
, Last price
HKD
Name
COMMON SPLENDOR INTL HLTH INDSTRY GP LTD
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Aidigong Maternal & Child Health Limited functions as an investment holding entity, delivering a diverse portfolio of postpartum care and health-related services throughout both the People's Republic of China and Hong Kong. Its operational framework is segmented into Postpartum Care Services, the Health Industry, and other ancillary activities. The company's offerings are extensive, encompassing maternal and pediatric healthcare, medical anti-aging treatments, healthcare industry investments, and the development of healthcare properties. Furthermore, it facilitates trade in natural health foods and pharmaceutical products. Aidigong also extends its expertise to precision life healthcare, bio-medical technology, and various management services, alongside investment and financial solutions. The firm, previously known as Common Splendor International Health Industry Group Limited, transitioned to its current name in December 2019. Its corporate headquarters are situated in Kowloon Bay, Hong Kong.
Key people
Wai Kuen Cheung
Executive Chairman of the Board · since 2012
King Ho Lam
Financial Controller · since 2017
Jiang Lin
Executive Director · since 2020
Jiong Xian Ye
Chief Executive Officer, Executive Director · since 2015
Company Secretary · since 2017
Hau Yan Cheng
Executive Deputy Chairman of the Board · since 2015
Kin Man Wong
Non-Executive Director · since 2019
Independent Non-Executive Director · since 2016
Yang Guang Mai
Independent Non-Executive Director · since 2013
Non-Executive Independent Director · since 2017
Valuation
Title HKD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||